Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 103 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016', provides in depth analysis on Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted pipeline therapeutics. 

The report provides comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) 
- The report reviews Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Overview 9
Therapeutics Development 10
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Products under Development by Stage of Development 10
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Products under Development by Therapy Area 11
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Products under Development by Indication 12
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Products Glance 14
Late Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Products under Development by Companies 17
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Products under Development by Universities/Institutes 20
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Therapeutics Assessment 23
Assessment by Monotherapy/Combination Products 23
Assessment by Mechanism of Action 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Companies Involved in Therapeutics Development 29
BioApex, s.r.o. 29
C4X Discovery Holdings PLC 30
Catabasis Pharmaceuticals, Inc. 31
Evgen Pharma Plc 32
Ixchel Pharma, LLC 33
Jiangsu Hengrui Medicine Co., Ltd. 34
Reata Pharmaceuticals, Inc. 35
Rigel Pharmaceuticals, Inc. 36
XenoPort, Inc. 37
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Drug Profiles 38
BA-1521 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
bardoxolone methyl - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
CAT-4001 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
dimethyl fumarate DR - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
IXC-101 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
IXC-103 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
LH-503 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
LH-526 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
MG-132 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
MIND-4 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
monosodium luminol - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
omaveloxolone - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
R-970 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
SFX-02 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
SFX-03 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Small Molecule to Activate Nrf2 for Inflammation - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
Small Molecules to Activate NRF-2 for COPD and Multiple Sclerosis - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Small Molecules to Activate Nrf2 for Cancer and Inflammation - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Small Molecules to Activate Nrf2 for Inflammation - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Small Molecules to Activate Nrf2 for Oncology and Inflammation - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Sulforadex - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
TBE-31 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
trigonelline hydrochloride - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
VEDA-1209 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
XP-23829 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Dormant Projects 78
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Discontinued Products 83
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Featured News & Press Releases 84
Jul 05, 2016: Bach Pharma Appoints Kelly Blackburn as Chief Executive Officer 84
Jun 23, 2016: Reata Pharmaceuticals Announces Interim Data From Extension Phase 2 LARIAT Study in Pulmonary Arterial Hypertension 84
May 03, 2016: Evgen Pharma: First Patient Dosed in Phase II Clinical Trial in SAH 85
Apr 18, 2016: TECFIDERA Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness 85
Apr 12, 2016: Biogen to Present Data on TECFIDERA at 2016 AAN Annual Meeting 88
Mar 02, 2016: Approval of Phase II Clinical Trial in SAH 89
Jan 19, 2016: FARA Announces Catabasis Pharmaceuticals as the Recipient of the Kyle Bryant Translational Research Award to Evaluate CAT-4001 as a Potential Therapy for Friedreich's Ataxia 90
Jan 05, 2016: Reata Enrolls First Patient with Pulmonary Hypertension Associated with Interstitial Lung Disease in LARIAT, a Phase 2 Study Examining Bardoxolone Methyl for the Treatment of Patients with Pulmonary Hypertension 90
Oct 27, 2015: Reata Announces Initial Phase 2 Pulmonary Arterial Hypertension Data for Bardoxolone Methyl and Planned Initiation of Phase 3 Study 91
Oct 23, 2015: Updated recommendations to minimize the risk of the rare brain infection PML with Tecfidera 93
Oct 07, 2015: New Data Show Strong, Sustained Effects of TECFIDERA in Newly-Diagnosed and Early Disease Course Multiple Sclerosis Patients 95
Oct 01, 2015: Biogen to Highlight Broad Research Commitment to MS Care at ECTRIMS Congress, On New TECFIDERA Data Demonstrating Importance of Early Treatment 98
Sep 16, 2015: Reata to Present Initial Phase 2 Data on Bardoxolone Methyl, a Novel Experimental Therapy for Pulmonary Hypertension Used in Patients on Stable Background PAH Therapy 99
Sep 15, 2015: XenoPort Announces Positive Phase 2 Study Results for XP23829 as a Potential Treatment for Patients with Psoriasis 99
Sep 02, 2015: USPTO Dismisses Inter Partes Review Petition of Biogen's Patent 514 for TECFIDERA (Dimethyl Fumarate) 101
Appendix 102
Methodology 102
Coverage 102
Secondary Research 102
Primary Research 102
Expert Panel Validation 102
Contact Us 102
Disclaimer 103

List of Tables

Number of Products under Development for, H2 2016 10
Number of Products under Development by Therapy Area, H2 2016 11
Number of Products under Development by Indication, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 14
Comparative Analysis by Early Stage Products, H2 2016 15
Comparative Analysis by Unknown Stage Development, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Development by Companies, H2 2016 (Contd..1) 19
Number of Products under Investigation by Universities/Institutes, H2 2016 20
Products under Investigation by Universities/Institutes, H2 2016 21
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 22
Assessment by Monotherapy/Combination Products, H2 2016 23
Number of Products by Stage and Mechanism of Action, H2 2016 24
Number of Products by Stage and Route of Administration, H2 2016 26
Number of Products by Stage and Molecule Type, H2 2016 28
Pipeline by BioApex, s.r.o., H2 2016 29
Pipeline by C4X Discovery Holdings PLC, H2 2016 30
Pipeline by Catabasis Pharmaceuticals, Inc., H2 2016 31
Pipeline by Evgen Pharma Plc, H2 2016 32
Pipeline by Ixchel Pharma, LLC, H2 2016 33
Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 34
Pipeline by Reata Pharmaceuticals, Inc., H2 2016 35
Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 36
Pipeline by XenoPort, Inc., H2 2016 37
Dormant Projects, H2 2016 78
Dormant Projects (Contd..1), H2 2016 79
Dormant Projects (Contd..2), H2 2016 80
Dormant Projects (Contd..3), H2 2016 81
Dormant Projects (Contd..4), H2 2016 82
Discontinued Products, H2 2016 83